The prognostic roles of hypogammaglobulinemia and hypocomplementemia in newly diagnosed diffuse large B-cell lymphoma

References

• Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74–87.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice. Clin Cancer Res. 2011;17(19):6112–6117.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121–3127.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–842.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313–2323.
   PubMed Web of Science ®Google Scholar
• Hong F, Kahl BS, Gray R. Incremental value in outcome prediction with gene expression-based signatures in diffuse large B-cell lymphoma. Blood. 2013;121(1):156–158.
   PubMed Web of Science ®Google Scholar
• Reda G, Cassin R, Gentile M, et al. IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia. Leukemia. 2019;33(6):1519–1522.
   PubMed Web of Science ®Google Scholar
• Andersen MA, Vojdeman FJ, Andersen MK, et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death. Leuk Lymphoma. 2016;57(7):1592–1599.
   PubMed Web of Science ®Google Scholar
• Troppan KT, Schlick K, Deutsch A, et al. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. Br J Cancer. 2014;111(1):55–60.
   PubMed Web of Science ®Google Scholar
• Prochazka KT, Melchardt T, Posch F, et al. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients. Br J Cancer. 2016;115(10):1264–1272.
   PubMed Web of Science ®Google Scholar
• Troppan KT, Melchardt T, Deutsch A, et al. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients. Eur J Haematol. 2015;95(6):538–544.
   PubMed Web of Science ®Google Scholar
• Melchardt T, Troppan K, Weiss L, et al. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2-microglobulin. Br J Haematol. 2015;168(2):239–245.
   PubMed Web of Science ®Google Scholar
• Gao R, Liang JH, Wang L, et al. Low T3 syndrome is a strong prognostic predictor in diffuse large B cell lymphoma. Br J Haematol. 2017;177(1):95–105.
   PubMed Web of Science ®Google Scholar
• Garg K, Maurer M, Griss J, et al. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome. Hum Pathol. 2016;54:157–164.
   PubMed Web of Science ®Google Scholar
• Brent J, Guzman D, Bangs C, et al. Clinical and laboratory correlates of lung disease and cancer in adults with idiopathic hypogammaglobulinaemia. Clin Exp Immunol. 2016;184(1):73–82.
   PubMed Web of Science ®Google Scholar
• Zenone T, Souillet G. Cancer et déficit primitif de l'immunité humorale [Cancer and primary humoral immunodeficiency]. Bull Cancer. 1997;84(8):813–821.
   PubMedGoogle Scholar
• Eissing M, Ripken L, Schreibelt G, et al. PTEN hamartoma tumor syndrome and immune dysregulation. Transl Oncol. 2019;12(2):361–367.
   PubMed Web of Science ®Google Scholar
• Cui J, Chen Y, Wang HY, et al. Mechanisms and pathways of innate immune activation and regulation in health and cancer. Hum Vaccin Immunother. 2014;10(11):3270–3285.
   PubMed Web of Science ®Google Scholar
• Zavadova E, Vocka M, Spacek J, et al. Cellular and humoral immunodeficiency in breast cancer patients resistant to hormone therapy. Neoplasma. 2014 61(1):90–98.
   PubMed Web of Science ®Google Scholar
• Castino GF, Cortese N, Capretti G, et al. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Oncoimmunology. 2016;5(4):e1085147.
   PubMed Web of Science ®Google Scholar
• Chernova NG, Soboleva NP, Mariina SA, et al. Immunoglobulinopathies in patients with angioimmunoblastic T-cell lymphoma. Ter Arkh. 2018;90(7):51–56.
   PubMed Web of Science ®Google Scholar
• Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015; 126(5):573–581.
   PubMed Web of Science ®Google Scholar
• Quinti I, Soresina A, Spadaro G, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immuno. 2007;27(3):308–316.
   PubMed Web of Science ®Google Scholar
• Mellemkjaer L, Hammarstrom L, Andersen V, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol. 2002;130(3):495–500.
   PubMed Web of Science ®Google Scholar
• Martin K, Maciej MM. Targeting complement-mediated immunoregulation for cancer immunotherapy. Semin Immunol. 2018;37:85–97.
   PubMed Web of Science ®Google Scholar
• Vahid AK. The role of the complement system in cancer. J Clin Invest. 2017;127(3):780–789.
   PubMed Web of Science ®Google Scholar
• Michael CC, David EI. Regulation of humoral immunity by complement. Immunity. 2012;37(2):199–207.
   PubMed Web of Science ®Google Scholar
• Kleczko EK, Kwak JW, Schenk EL, et al. Targeting the complement pathway as a therapeutic strategy in lung cancer. Front Immunol. 2019;10:954.
   PubMed Web of Science ®Google Scholar
• Feugier P. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. Future Oncol. 2015;11(9):1327–1342.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
   Google Scholar